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 Introduction 
A significant percentage of patients with diabetes develop chronic kidney disease 
(CKD), and diabetes is also a leading cause of end-stage renal disease.1 More 
than a quarter of patients who are on dialysis in the UK have diabetes.2 Diabetic 
kidney disease is associated with high morbidity and mortality, which are 
predominantly related to cardiovascular complications and the progression of 
kidney disease requiring renal replacement therapy. Hypertension is a modifiable 
risk factor for cardiovascular complications and progression of CKD.3  
The recommendations outlined here are for the variety of clinicians who 
manage patients with diabetic kidney disease, including GPs and specialists in 
diabetes, cardiology and nephrology. They are intended to harmonise practices 
of blood pressure monitoring, and pharmacological and non-pharmacological 
management of hypertension, which may vary considerably. 
 
Evidence grades for the recommendations 
The following evidence grading has been used to determine the strength of the 
recommendations, the suggested audit standards and the questions for areas 
that require future research. 
1A – Strong recommendation: high-quality evidence 
1B – Strong recommendation: moderate-
quality evidence  
1C – Strong recommendation: low-quality 
evidence 
1D – Strong recommendation: very low-
quality evidence  
2A – Weak recommendation: high-quality 
evidence 
2B – Weak recommendation: moderate-
quality evidence  
2C – Weak recommendation: low-quality 
evidence 
2D – Weak recommendation: very low-quality evidence 
 1 Hypertension management and renin-angiotensin-aldosterone 
system blockade in patients with type 1 diabetes 
 
Recommendations 
The following are recommendations for renin-angiotensin-aldosterone system 
(RAAS) blockade and hypertension management in patients with type 1 diabetes. 
1 In patients with type 1 diabetes and normoalbuminuria, we suggest a threshold 
for blood pressure therapy of a persistent upright (sitting or standing) blood 
pressure that is greater than or equal to 140/80 mmHg (Grade 2D). 
In children and adolescents with type 1 diabetes, hypertension is defined as 
average systolic blood pressure and/or diastolic blood pressure that is greater 
than the 95th percentile for the patient’s gender, age and height on more than 
three occasions (Grade 1B). 
2 We recommend that angiotensin-converting-enzyme inhibitor (ACEI) therapy 
should be used as a first-line agent for blood pressure lowering and, if ACEI 
therapy is contraindicated or not tolerated, angiotensin receptor blockers (ARBs) 
should be considered (Grade 1B). 
3 In most adults with type 1 diabetes and persistent microalbuminuria or 
macroalbuminuria, we recommend that ACEI therapy should be considered 
irrespective of blood pressure, and that the target upright blood pressure should 
be less than or equal to 130/80 mmHg. We recommend that the dose of ACEI 
should be titrated to the maximum tolerated (Grade 1B). 
4 There is no current evidence to support a role for ACEI therapy for blood 
pressure control or renal protection in patients with type 1 diabetes who are 
normotensive and normoalbuminuric (Grade 1C). 
5 There is some evidence to support the use of candesartan to prevent the 
development or progression of retinopathy in patients with type 1 diabetes 
who are normotensive and normoalbuminuric (Grade 1C). 
6 There is no firm evidence to support a role of dual blockade of the RAAS in 
patients with type 1 diabetes (Grade 1C). 
7 We recommend that women of childbearing age should be encouraged to stop 
 RAAS-blocking drugs prior to actively considering pregnancy (Grade 1B). 
8 We suggest that patients with type 1 diabetes with significant renal function 
impairment (estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m2) 
should be advised to withhold RAAS-blocking drugs during periods of acute illness 
(not graded). 
 
Audit standards 
The following are suggested as audit standards for RAAS blockade and hypertension 
management in patients with type 1 diabetes. 
1 The proportion of patients with type 1 diabetes with micro- or 
macroalbuminuria who are treated with an ACEI or ARB at the maximum 
tolerated doses. 
2 The proportion of patients with type 1 diabetes with micro- or 
macroalbuminuria who are achieving blood pressure of less than 130/80 
mmHg. 
3 The proportion of patients with type 1 diabetes and albuminuria who are on 
submaximal doses of ACEIs or ARBs due to hyperkalaemia or adverse 
reactions. 
 
Areas that require further research 
The following areas lack good-quality evidence for RAAS blockade and 
hypertension management in patients with type 1 diabetes, and hence further 
research is necessary. 
1 In light of the fact that the presence of microalbuminuria in patients with type 1 
diabetes may not be the best predictor of whether they will develop progressive 
renal disease, what is the role for other markers (such as kidney injury molecule-
1 (KIM-1)) in predicting the risk of renal disease in patients with type 1 diabetes? 
 
2 What is the role of dual RAAS blockade in patients with type 1 diabetes and 
nephropathy? 
3 What is the role of aldosterone receptor blockers or direct renin inhibitors in 
patients with type 1 diabetes and nephropathy? 
 4 Is there a role for home or ambulatory blood pressure monitoring in the 
diagnosis and management of hypertension in patients with type 1 diabetes, 
particularly in those who have diabetic autonomic neuropathy? 
5 Does measurement of plasma renin activity have a role in screening and 
managing hypertension in patients with type 1 diabetes? 
6 Does tight glycaemic control and blood pressure lowering reduce the 
incidence of patients developing microvascular complications? 
7 What is the role of RAAS-blocking agents in patients who have type 1 diabetes, 
progressive renal decline and normoalbuminuria? 
 2 Hypertension management and renin-angiotensin-aldosterone 
system blockade in patients with type 2 diabetes, nephropathy 
and/or early chronic kidney disease (stages 1–3) 
 
Recommendations 
The following are recommendations for RAAS blockade and hypertension 
management in patients with type 2 diabetes, nephropathy and/or early CKD. 
1 In patients with type 2 diabetes and hypertension, we recommend salt intake 
of less than 90 mmol per day (less than 2 g per day of sodium – equivalent to 
5 g of sodium chloride) (Grade 1C). 
2 In patients with type 2 diabetes, CKD and urine albumin excretion rate (AER) of 
less than 30 mg per 24 hours (albumin:creatinine ratio (ACR) less than 3 
mg/mmol), we recommend that their target upright blood pressure should be less 
than 140/90 mmHg (Grade 1D). 
3 In patients with type 2 diabetes, CKD and urine AER of greater than 30 mg per 24 
hours (ACR greater than 3 mg/mmol), we suggest aiming for a target upright 
blood pressure that is consistently less than 130/80 mmHg (Grade 2D). 
4 There is no evidence to support either ACEI or ARB therapy as first-line blood 
pressure lowering agents in comparison with other antihypertensive agents in 
patients with type 2 diabetes, normal renal function and normal urine AER (less 
than 30 mg per 24 hours or ACR less than 3 mg/mmol) (Grade 1A). 
5 We suggest that ACEIs (or ARBs if ACEIs are not tolerated) should be 
preferentially used in patients with type 2 diabetes and CKD who have urine 
AER above 30 mg per 24 hours (ACR greater than 3 mg/mmol). We suggest 
that the dose of ACEI (or ARB) should be titrated to the maximum tolerated 
(Grade 2D). 
6 There is currently no evidence to support the role of home or ambulatory 
blood pressure monitoring in patients with type 2 diabetes and CKD stages 
2 and 3 (Grade 1D). 
7 There is currently no evidence to support the role of dual blockade of the RAAS 
in patients with type 2 diabetes and CKD stages 1–3 (Grade 1B). 
 8 Upright blood pressure targets should be set at no lower than 150/90 mmHg in 
those with type 2 diabetes who are aged 80 years or over (Grade 2B). 
9 We suggest that patients with type 2 diabetes with significant renal function 
impairment (eGFR <45 ml/min/1.73 m2) should be advised to withhold RAAS-
blocking drugs during periods of acute illness (not graded). 
 
Audit standards 
The following are suggested as audit standards for RAAS blockade and 
hypertension management in patients with type 2 diabetes, early CKD and/or 
albuminuria. 
1 The percentage of patients with type 2 diabetes who have CKD and urine AER 
of greater than 30 mg per 24 hours (ACR greater than 3 mg/mmol) who are 
achieving the target upright blood pressure of less than 130/80 mmHg. 
2 The proportion of patients with type 2 diabetes who have CKD and urine AER of 
greater than 30 mg per 24 hours (ACR greater than 3 mg/mmol) who are on 
ACEIs or ARBs. 
3 The percentage of patients with type 2 diabetes who have CKD and urine AER of 
greater than 30 mg per 24 hours (ACR greater than 3 mg/mmol) who are not on 
ACEIs or ARBs (or who are on a suboptimal dosage) due to hyperkalaemia or a 
decrease in eGFR of greater than 25% or an increase in serum creatinine of 
greater than 30%. 
 
4 The number of patients with type 2 diabetes and CKD who are on dual blockade of 
the RAAS. 
 
Areas that require further research 
The following areas lack good-quality evidence for RAAS blockade and 
hypertension management in patients with type 2 diabetes, nephropathy and/or 
early CKD, and hence further research is necessary. 
1 What is the best method for blood pressure measurement in patients with type 2 
diabetes who have CKD? 
2 What is the evidence-based lower limit for blood pressure reduction in 
 patients with type 2 diabetes who have CKD? 
3 Does reduction in albuminuria with agents that do not modify blood pressure 
improve hard cardiovascular and renal outcomes? 
4 Should RAAS inhibition be maximised in patients with CKD? 
5 Can potassium binders enable a higher dosage of RAAS inhibitors with 
better attainment of blood pressure control and reduction in hyperkalaemia? 
6 Is the use of mineralocorticoid antagonists beneficial in patients with type 2 
diabetes and nephropathy? 
7 What are the best second- and third-line blood pressure lowering agents in 
patients with type 2 diabetes who have CKD and albuminuria? 
8 Is there a need for long-term outcome studies of non-dihydropyridine calcium 
channel blockers in diabetic nephropathy? 
 3 Hypertension management and renin-angiotensin-aldosterone system 
blockade in patients with type 2 diabetes, nephropathy and/or later stage 
chronic kidney disease (stages 4 and 5, non-dialysis) 
 
Recommendations 
The following are recommendations for the management of hypertension in patients 
with diabetes and CKD stages 4 and 5 (non-dialysis). 
1 We recommend regular monitoring of blood pressure, urine albumin, blood 
electrolytes and kidney function in patients with diabetes and CKD stages 4 
and 5 (Grade 1B). 
2 We recommend that if blood pressure is uncontrolled, electrolytes are abnormal 
or kidney disease is progressive, they should be monitored two to four times per 
year, depending on the stage of CKD and the patient’s need (Grade 1C). 
3 We recommend that all patients with diabetes, advanced CKD and high blood 
pressure follow a low-salt (sodium chloride) diet, ideally restricted to less than 5 
g per day (Grade 1B). 
4 We recommend the initiation of antihypertensive agents in patients who have 
diabetes and CKD stages 4 and 5 and an ACR of less than 30 mg/mmol when 
their blood pressure is greater than 140/90 mmHg. We also recommend aiming 
for a target upright blood pressure of less than or equal to 140/90 mmHg during 
therapy (Grade 1B). 
5 We suggest initiation of antihypertensive agents in patients with diabetes and 
CKD stages 4 and 5 and an ACR of greater than 30 mg/mmol when their blood 
pressure is greater than 130/80 mmHg, and we suggest aiming for a target 
upright blood pressure of less than or equal to 130/80 mmHg (Grade 2C). 
6 We recommend the use of an ACEI (or ARB if ACEI is not tolerated) as the 
first choice blood pressure lowering agent in patients with diabetes and CKD 
stages 4 and 5 and micro- or macroalbuminuria. We recommend that the 
dose of ACEI (or ARB) should be titrated to the maximum tolerated (Grade 
1B). 
7 We do not recommend the use of combinations of ACEIs and ARBs in patients 
 with diabetes and CKD stages 4 and 5 (Grade 1C). 
8 We suggest dietary advice, correction of acidosis and loop diuretic therapy to 
lower serum potassium as necessary in patients with diabetes and CKD stages 4 
and 5 for safe use of an ACEI (or ARB). In the presence of hyperkalaemia, 
where bicarbonate is less than 22 mmol/l, sodium bicarbonate can be added at a 
dose of 500 mg twice daily: larger doses can be used but often require a 
concomitant increase or addition of a loop diuretic dose (not graded). 
9 We suggest that patients with type 2 diabetes and advanced CKD should be 
advised to withhold RAAS-blocking drugs during periods of acute illness (not 
graded). 
 
Audit standards 
The following are suggested as audit standards for the management of 
hypertension and RAAS blockade in patients with diabetes and CKD stages 4 
and 5. 
1 The proportion of patients with blood pressure less than or equal to 140/90 
mmHg who have diabetes and CKD stages 4 and 5 with an ACR of less than 
30 mg/mmol. 
2 The proportion of patients with blood pressure less than or equal to 130/80 
mmHg who have diabetes and CKD stages 4 and 5 with an ACR of greater 
than 30 mg/mmol. 
3 The proportion of patients who are taking an ACEI or ARB and have a serum 
potassium greater than 5.5 mmol/l. 
4 The proportion of patients who have a potassium level of greater than 5.5 mmol/l 
and are being seen by a dietitian. 
 
5 The proportion of patients who are not on ACEIs or ARBs (or who are on a 
submaximal dosage) due to hyperkalaemia (greater than 5.5 mmol/l) or a 
decrease in eGFR of greater than 25%. 
6 The number of patients with type 2 diabetes and CKD who are on dual blockade of 
the RAAS. 
  
Areas that require further research 
The following areas lack good-quality evidence for the management of hypertension 
in patients with diabetes and CKD stages 4 and 5, and hence further research is 
necessary. 
1 What is the effect of intensive blood pressure lowering (less than or equal to 
130/80 mmHg) on renal and cardiac outcomes in patients with diabetes and 
CKD stages 4 and 5? 
2 What is the impact of dual blockade with an ACEI and ARB on renal and 
cardiac outcomes in patients with diabetes, CKD stages 4 and 5 and 
albuminuria? 
3 What is the impact of aldosterone blockade on renal and cardiac outcomes in 
patients who have diabetes and CKD stages 4 and 5? 
4 What is the effect of long-term use of novel potassium binders together with 
RAAS blockade on renal and cardiac outcomes in patients with diabetes and 
CKD stages 4 and 5? 
 4 Hypertension management in patients with diabetes and chronic kidney 
disease who are on dialysis (stage 5D) 
 
Recommendations 
The following are recommendations for blood pressure control in patients with 
diabetes and CKD stage 5D. 
 
1 We recommend that ambulatory blood pressure measurement or home blood 
pressure measurement should be used to monitor blood pressure in patients 
with diabetes who are on dialysis (Grade 1C). 
2 Where ambulatory blood pressure measurement or home measurement are 
not feasible to monitor blood pressure in patients with diabetes who are on 
dialysis, we suggest using pre-, intra- and post-dialysis blood pressure 
measurements for patients who are on haemodialysis, and using clinic blood 
pressure measurements for patients who are on peritoneal dialysis (Grade 2D). 
 
3 We recommend volume control as a first-line management to optimise blood 
pressure control in patients with diabetes who are on dialysis (Grade 1B). 
 
4 We suggest salt restriction to less than 5 g per day to optimise blood pressure 
control in patients with diabetes who are on dialysis (Grade 2C). 
5 We suggest a target upright interdialytic blood pressure of less than 140/90 
mmHg for patients with diabetes who are on dialysis. Individualisation of the 
blood pressure target may be indicated in other patients who are burdened with 
multiple comorbidities, in order to reduce adverse events of blood pressure 
lowering (Grade 2D). 
6 We recommend that intradialytic hypotension should be avoided in patients with 
diabetes who are on haemodialysis (Grade 1B). 
7 We suggest using ACEIs or ARBs (but not in combination), beta-blockers and 
calcium channel blockers to reduce cardiovascular complications in patients with 
diabetes and hypertension who are on dialysis (Grade 2B). 
8 We suggest the use of diuretics in patients with diabetes who are on dialysis 
 and have residual renal function (Grade 2C). 
 
Audit standards 
The following are suggested as audit standards for blood pressure control in 
patients who have diabetes and CKD stage 5D. 
1 The proportion of patients with diabetes who are on dialysis who achieve an 
upright interdialytic blood pressure target of less than 140/90 mmHg. 
2 The proportion of patients with diabetes who are on dialysis who achieve an 
upright interdialytic blood pressure target of less than 140/90 mmHg without the 
use of blood pressure lowering medication. 
3 The proportion of patients with diabetes who are on dialysis with an interdialytic 
blood pressure of greater than 140/90 mmHg who are not being treated with 
ACEIs, ARBs, beta-blockers or calcium channel blockers in whom such drugs are 
not contraindicated. 
4 The proportion of patients with diabetes who are on dialysis and on 
diuretics following commencement of dialysis. 
 
Areas that require further research 
The following areas lack good-quality evidence for blood pressure control in 
patients with diabetes and CKD stage 5D, and hence further research is 
necessary. 
1 Which blood pressure measurement should be used to predict left ventricular 
hypertrophy (LVH) and mortality in patients with diabetes who are on dialysis: 
pre-dialysis, post-dialysis, home or ambulatory blood pressure measurement? 
2 What is the optimal upright blood pressure target for patients with diabetes who are 
on dialysis? 
3 Can bioimpedance spectroscopy devices be used to determine a target weight 
and predict the risk of cardiovascular morbidity and mortality in patients with 
diabetes who are on dialysis? 
4 Does treatment with ACEIs, ARBs, beta-blockers or calcium channel 
blockers to lower blood pressure in patients with diabetes who are on 
 dialysis reduce cardiovascular morbidity and mortality? 
5 Is there a role for diuretic therapy in patients with diabetes who are on dialysis 
and have residual renal function? 
6 Does strict salt restriction (to less than 5 g per day versus less than 6 g per day) 
in patients with diabetes who are on dialysis influence blood pressure control or 
cardiovascular outcome? 
 Table 1 Blood pressure targets in patients with diabetes through stages of kidney function 
impairment 
 
 Stage of kidney function impairment 
Normal kidney 
function, 
normoalbumin
uria 
Normal kidney 
function, 
microalbumin
uria 
CKD 1–3 CKD 4–5 
(non-
dialysis) 
CKD 5 
(dialysis) 
Type 1 
diabetes in 
mmHg 
(evidence 
grade) 
≤140/80 (2D) ≤130/80 (1B) ≤130/80 (1B) ≤140/90 (1B) 
≤130/80 for 
albuminuric
(2C) 
≤140/90 (2D) 
(interdialytic 
BP) 
Type 2 
diabetes in 
mmHg 
(evidence 
grade) 
≤140/90 (1D) 
≤150/90 (2B) 
(for ≥80 years) 
≤130/80 (2D) ≤130/80 
(2D) 
≤140/90 (1B) 
≤130/80 for 
albuminuric 
(2C) 
≤140/90 (2D) 
(interdialytic 
BP) 
CKD, chronic kidney disease; BP, blood pressure. 
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